DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183483

Efficacy, safety and cost effectiveness of levocetrizine and ebastine in allergic rhinitis: a comparative study

Sharadashri Rao, Sunil Pai, Kuladeepa Ananda Vaidya, Tara V. Shanbhag

Abstract


Background: Allergic rhinitis is a ubiquitous aliment affecting a large population of individuals. The mainstay of treatment includes antihistamines and topical steroids. With a large assortment available, the choice of the drugs needs to be non-random and evidenced based. Hence this study was undertaken to compare Levocetrezine and Ebastine in terms of efficacy, safety and cost effectiveness in treatment of allergic rhinitis.

Methods: Newly diagnosed patients with allergic rhinitis were categorized into two groups and treated with Levocetrizine 5mg and Ebastine 20mg per day respectively. Severity of the symptoms at the commencement and at the end of second and the fourth weeks of therapy were assessed using a four-point Likert scale and assigning a Total Nasal Symptoms Score (TNSS). The primary efficacy measure was mean change from baseline TNSS at each follow up visit. Change in TNSS was compared using Independent sample test. Adverse effects in both the groups were compared using Chi square test. Cost effectiveness was inferred by calculation of the Average Cost Effectiveness Ratio.

Results: A total of 159 patients 84 from Levocetrizine group (L group) and 75 from the Ebastine group (E group) were available for study. At the end of second week, the E group showed a better reduction in TNSS(p-0.04). However, both the groups showed similar reduction in TNSS at the concluding visit (p-value of 0.09). The incidence of adverse effects was significantly higher in the L than in E. Levocetrezine was found to be more cost effective than Ebastine.

Conclusions: Levocterezine and Ebastine are equally efficacious in treatment of allergic rhinitis. Hence treatment will have to be personalized to the individual patients based on other factors such as adverse drug effects and cost effectiveness.

Keywords


Allergic rhinitis, Cost-effectiveness Ebastine, Efficacy, Levocetrezine

Full Text:

PDF

References


Stubner P, Zieglmayer, Horak F. A direct comparison of the efficacy of antihistamines in sar and par: randomised,placebo- controlled studies with levocetirizine and loratadine using an environmental exposure unit- The Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20(6):1-6

Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, Peat JK, Salome CM. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite‐sensitive subjects. Allergy. 2004 Apr;59(4):406-14.

Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. Proceedings of the Am Thoracic Soc. 2011 Mar 1;8(1):121-31.

Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. American Health Drug Benefits. 2008;1(8):26-33.

Mösges R, König V, Köberlein J. The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis:a meta-analysis. Allergology International. 2011 Jan 1;60(4):541-6.

Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. 11th Ed. New Delhi: Tata McGraw Hill Education Private Limited;2009;278.

Tripathi KD. Essentials of Medical Pharmacology.7th ed. New Delhi: Jaypee Brothers Medical Publishers (P)Ltd;2014;166-7.

Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy. 2009;64(1):85-95.

Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2011;7(1):1-8.

Skidgel RA, Kaplan AP, Erdos EG. Histamine, Bradykinin and Their antagonist: Goodman and Gilman’s The pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill;2011;925.

Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagnos Res: JCDR. 2017 Mar;11(3):WC06.

Ciprandi G. Clinical utility and patient adherence with ebastine for allergic rhinitis. Patient Prefer Adherence. 2010;4:389-95.